Short Interest Coverage: Syros Pharmaceuticals Incorporated (NASDAQ:SYRS)’s Stock Is Sell After More Market Selling

November 17, 2016 - By Adrian Mccoy   ·   0 Comments

Short Interest Coverage: Syros Pharmaceuticals Incorporated (NASDAQ:SYRS)'s Stock Is Sell After More Market Selling

The stock of Syros Pharmaceuticals Incorporated (NASDAQ:SYRS) registered an increase of 52.7% in short interest. SYRS’s total short interest was 124,300 shares in November as published by FINRA. Its up 52.7% from 81,400 shares, reported previously. With 23,200 shares average volume, it will take short sellers 5 days to cover their SYRS’s short positions. The short interest to Syros Pharmaceuticals Incorporated’s float is 1.76%. The stock decreased 1.65% or $0.22 during the last trading session, hitting $13.1. Syros Pharmaceuticals Inc (NASDAQ:SYRS) has risen 6.00% since October 18, 2016 and is uptrending. It has outperformed by 1.38% the S&P500.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $319.89 million. The Firm is focused on developing treatments for cancer and immune-mediated diseases. It currently has negative earnings. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

SYRS Company Profile

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Firm is focused on developing treatments for cancer and immune-mediated diseases, and is building a pipeline of gene control medicines. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets. The Company’s drug programs include SY-1425 and SY-1365. SY-1425 (tamibarotene) is an oral and selective agonist, or activator, of the transcription factor RARa. The Firm is involved in advancing SY-1425 into genomically defined patient populations with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). SY-1365 is a selective small molecule inhibitor of the transcriptional kinase known as cyclin-dependent kinase 7 (CDK7).

More notable recent Syros Pharmaceuticals Inc (NASDAQ:SYRS) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on June 06, 2016, also Bostonglobe.com with their article: “Syros Pharmaceuticals registers to go public” published on June 04, 2016, Marketwatch.com published: “Syros Pharmaceuticals sets IPO price expectations” on June 20, 2016. More interesting news about Syros Pharmaceuticals Inc (NASDAQ:SYRS) were released by: Businesswire.com and their article: “Syros Pharmaceuticals Closes $40 Million Preferred Stock Financing” published on January 12, 2016 as well as Businesswire.com‘s news article titled: “Syros Pharmaceuticals Appoints Kyle Kuvalanka as Chief Operating Officer” with publication date: September 21, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Adrian Mccoy


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>